Trial Profile

A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VBI 1901 (Primary) ; VBI 1901 (Primary) ; AS01B; Carmustine; Granulocyte macrophage colony stimulating factor; Lomustine
Indications Glioblastoma
Focus Adverse reactions; First in man
Sponsors VBI Vaccines

04 Jun 2024 Based on part 1 results the study was amended into a randomized study.
04 Jun 2024 Trial design of phase IIb (As of January 31st 2024 , n=12 ) presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
29 May 2024 According to VBI vaccine media release, data of this trial will be presented in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on Saturday, June 1, 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com